MedPath

epidermise sheet cultured from autologous revertant somatic mosaic site (epidermise sheet cultured from autologous revertant somatic mosaic site)

Completed
Conditions
epidermolytic ichthyosis
Registration Number
jRCTb041190097
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
3
Inclusion Criteria

Patients who are diagnosed with epidermolytic ichthyosis and have a revertant somatic mutation, the responsible gene mutation * was identified by genetic testing.

  • Heterozygote mutation must be demonstrated in either keratin 1 (KRT1) or keratin 10 (KRT10).
Exclusion Criteria

Patients hypersensitive to penicillin, kanamycin, streptomycin, and amphotericin B antibiotics. Patients with a history of hypersensitivity to penicillin antibiotics and aminoglycoside antibiotics. Patients who are allergic to cattle, mice and pigs. Patients with malignant neoplastic lesions other than the skin, or patients with a history within 3 years prior to enrollment.

Study & Design

Study Type
Interventional
Study Design
single assignment
Primary Outcome Measures
NameTimeMethod
-

Improvement rate of hyperkeratosis 4 weeks after the final transplant (%)

Secondary Outcome Measures
NameTimeMethod
Average improvement rate of hyperkeratosis up to 24 weeks after initial transplantationup to 24 weeks after initial transplantation

Average improvement rate of hyperkeratosis up to 24 weeks after initial transplantation (%)

Average improvement rate of site-specific hyperkeratosis up to 24 weeks after initial transplantationup to 24 weeks after initial transplantation

Average improvement rate of site-specific hyperkeratosis up to 24 weeks after initial transplantation (%)

Improvement rate of site-specific hyperkeratosis 4 weeks after final transplantation4 weeks after final transplantation

Improvement rate of site-specific hyperkeratosis 4 weeks after final transplantation (%)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.